|
|
|
AFRICA: Concern over HIV/TB coinfection drug
[This report does not necessarily reflect the views of the United Nations]
JOHANNESBURG, 25 April (PLUSNEWS) - Experts are concerned that Isoniazid, an antibiotic commonly used to treat tuberculosis (TB) in HIV-positive people, might also result in multi-drug resistant TB (MDR-TB).
Ted Cohen of the Harvard School of Public Health developed a mathematical model that predicted Isoniazid use would reduce TB prevalence and mortality for several years but also would accelerate the development of MDR-TB.
The World Health Organisation recommends Isoniazid for people living with both HIV and TB to prevent latent TB from becoming active.
Cohen, however, noted in a statement: "We're not saying Isoniazid preventive therapy (IPT) policies are ill-advised, but they must be coupled with an understanding that large-scale IPT programmes should be ready to diagnose and treat individuals with MDR-TB as part of the programmes."
[ENDS]
:: MORE NEWS BRIEFS ::
|
|
|
|
|
|
|
| Links |
· AIDS Media Center
|
· The Global Fund to fight AIDS, Tuberculosis & Malaria
|
· International Community of Women Living with HIV/AIDS
|
· AEGIS
|
· International HIV/AIDS Alliance
|
PlusNews does not take responsibility for info in links supplied.
|
|
|
|
|
[Back] [Home Page]
Click here to send any feedback, comments or questions you have about PlusNews Website or if you prefer you can send an Email to Webmaster
Copyright © IRIN 2006
The material contained on www.PlusNews.org comes to you via IRIN, a UN humanitarian news and information service, but may not necessarily reflect the views of the United Nations or its agencies.
All PlusNews material may be reposted or reprinted free-of-charge; refer to the IRIN copyright page for conditions of use. IRIN is a project of the UN Office for the Coordination of Humanitarian Affairs.
|
